By Michael McCaughan
The first round of the legislative debate over health care reform in the US did not go pharma’s way.
Cost Effectiveness in the US? Round One Goes Against Pharma
The stimulus bill provides an unprecedented $1.1 billion for comparative effectiveness research-and does so with none of the key provisions biopharma companies hope to see as the US federal government takes a more active role in the field. The good news: this is only the first round, and there is reason to believe the field is evolving as most pharma companies would want. But this isn't the time for manufacturers to let their guard down.
More from Market Access
• By
Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.
• By
The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.
• By
ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.
• By
New rules requiring more granular drug pricing data to be disclosed in machine-readable files will go into effect in 2026.
More from Pink Sheet
• By
ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.
• By
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
• By
Extended-release stimulants will add a new ‘Limitation of Use’ about weight loss in children under 6 years, reflecting concerns about overuse from the Make America Healthy Again commission, a concern multiple studies did not find valid.